Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Host Private Seminar to Present MiQLab Data from Recent Study

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced that it will host a private event featuring Dr. Shelley Rankin, a professor of microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet). Attended by a select group of veterinarians, the private seminar will feature data compiled by Rankin based on her studies evaluating the use of LexaGene’s MiQLab to detect Staphylococcus in specimens gathered from canine skin infections. The event will also include information regarding the use of molecular diagnostics in veterinary medicine as well as analytical and clinical data generated using LexaGene’s MiQLab system. The studies performed by Rankin and LexaGene were designed to analyze and evaluate the performance of LexaGene’s MiQLab to detect common bacterial pathogens encountered in veterinary medicine. To conduct the analytical studies and clinical urine study, MiQLabs were equipped with LexaGene’s MiQLab(TM) Bacterial and AMR Test. The test is designed to screen for 7 common bacterial pathogens and 13 different antimicrobial resistance factors. Rankin noted that LexaGene’s MiQLab returns a molecular analysis on specimens in a fraction of the time it takes for culture to return results, enabling veterinarians to quickly identify infection and offer pet owners evidence-based treatment options. “Our goal has always been to have the MiQLab generate high-quality data inside veterinary clinics where veterinarians can use this data to guide treatment decisions,” said LexaGene CEO and founder Jack Regan in the press release. “These data prove we have achieved this goal. Our sales team will be using these data to secure sales in the veterinary market, which has relatively few options for quality in-hospital pathogen testing.” To view the full press release, visit https://ibn.fm/KxcH7 About LexaGene Holdings Inc.  LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com. NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF About MissionIRNewsBreaks MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation. MissionIR (MIR) Atlanta, Georgia www.MissionIR.com 404.941.8975 Office [email protected] Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
This entry was posted in LexaGene Holdings Inc. LXXGF. Bookmark the permalink.

Comments are closed.